LPA receptors: Subtypes and biological actions

Annual Review of Pharmacology and Toxicology

Volumn 50, Issue , 2010, Pages 157-186

  Choi, Ji Woong ^a   Herr, Deron R ^a   Noguchi, Kyoko ^a   Yung, Yun C ^a   Lee, Chang Wook ^a   Mutoh, Tetsuji ^a   Lin, Mu En ^a   Teo, Siew T ^a   Park, Kristine E ^a   Mosley, Alycia N ^a   Chun, Jerold ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Autotaxin; Brain; Cancer; Development; G protein coupled receptor; Lysophosphatidic acid

Indexed keywords

AUTOTAXIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 87; KI 6425; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHATIDIC ACID RECEPTOR 3; LYSOPHOSPHATIDIC ACID RECEPTOR 4; LYSOPHOSPHATIDIC ACID RECEPTOR 5; NSC 161613; NSC 16163; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y10 RECEPTOR; PURINERGIC P2Y5 RECEPTOR; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; VPC 12249; LYSOPHOSPHOLIPID;

ANGIOGENESIS; ASTHMA; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; BREAST CANCER; CARCINOGENESIS; CARDIOVASCULAR SYSTEM; CELL INTERACTION; DEVELOPMENT; DIGESTIVE SYSTEM CANCER; DISEASE MODEL; GROWTH; HUMAN; IMMUNE SYSTEM; IMPLANTATION; KIDNEY FIBROSIS; KIDNEY INJURY; LIVER FIBROSIS; LUNG CANCER; LUNG FIBROSIS; LYMPHOCYTE FUNCTION; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MYELINATION; NERVE INJURY; NERVOUS SYSTEM; NEUROPATHOLOGY; NONHUMAN; OBESITY; OVARY CANCER; PATHOPHYSIOLOGY; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR AFFINITY; REPERFUSION INJURY; REPRODUCTION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SPERMATOGENESIS; WOUND HEALING; ANIMAL; CARDIOVASCULAR FUNCTION; CLASSIFICATION; DRUG ANTAGONISM; DRUG POTENTIATION; FIBROSIS; METABOLISM; NEOPLASM; NERVOUS SYSTEM FUNCTION; PHYSIOLOGY;

MUS;

ANIMALS; CARDIOVASCULAR PHYSIOLOGICAL PROCESSES; FIBROSIS; HUMANS; IMMUNE SYSTEM; LYSOPHOSPHOLIPIDS; NEOPLASMS; NERVOUS SYSTEM PHYSIOLOGICAL PHENOMENA; OBESITY; RECEPTORS, LYSOPHOSPHATIDIC ACID; REPRODUCTION; SIGNAL TRANSDUCTION;

EID: 77949526409     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.010909.105753     Document Type: Review

References (209)

1. Hecht JH, Weiner JA, Post SR, Chun J. 1996. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell. Biol. 135:1071-1083
2. Choi JW, Lee CW, Chun J. 2008. Biological roles of lysophospholipid receptors revealed by genetic null mice: an update. Biochim. Biophys. Acta 1781:531-539
3. Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, et al. 2008. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol. Biol. Cell. 19:5435-5445
4. Lee M, Van Brocklyn J, Thangada S, Liu C, Hand A, et al. 1998. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279:1552-1555
5. Spiegel S, Milstien S. 2003. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell. Biol. 4:397-407
6. Chun J, Rosen H. 2006. Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. Curr. Pharm. Des. 12:161-171
7. Aoki J. 2004. Mechanisms of lysophosphatidic acid production. Semin. Cell. Dev. Biol. 15:477-489
8. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, et al. 1999. Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim. Biophys. Acta 1440:194-204
9. Sano T, Baker D, Virag T, Wada A, Yatomi Y, et al. 2002. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J. Biol. Chem. 277:21197-21206
10. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, et al. 2002. Autotaxin has lysophospho-lipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell. Biol. 158:227-233
11. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, et al. 2002. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277:39436-39442
12. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, et al. 1992. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267:2524-2529
13. Murata J, Lee HY, Clair T, Krutzsch HC, Arestad AA, et al. 1994. cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J. Biol. Chem. 269:30479-30484
14. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, et al. 2006. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 26:5015-5022
15. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, et al. 2006. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281:25822-25830
16. Fukushima N, Ishii I, Contos JJ, Weiner JA, Chun J. 2001. Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 41:507-534
17. Ishii I, Fukushima N, Ye X, Chun J. 2004. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73:321-354
18. Chun J. 2007. How the lysophospholipid got its receptor. Scientist 21:48-54
19. Contos JJ, Chun J. 1998. Complete cDNA sequence, genomic structure, and chromosomal localization of the LPA receptor gene, lpA1/vzg-1/Gpcr26. Genomics 51:364-378
20. Contos JJ, Ishii I, Chun J. 2000. Lysophosphatidic acid receptors. Mol. Pharmacol. 58:1188-1196
21. Ye X. 2008. Lysophospholipid signaling in the function and pathology of the reproductive system. Hum. Reprod. Update 14:519-536
22. An S, Bleu T, Hallmark OG, Goetzl EJ. 1998. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273:7906-7910 (Pubitemid 28168837)
23. OhuchiH, Hamada A, MatsudaH, Takagi A,Tanaka M, et al. 2008. Expression patterns of the lysophos-pholipid receptor genes during mouse early development. Dev. Dyn. 237:3280-3294
24. Weiner JA, Hecht JH, ChunJ.1998. Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelinationin the postnatal murine brain. J. Comp. Neurol.398:587-598
25. Weiner JA, ChunJ.1999. Schwann cell survival mediatedbythe signaling phospholipid lysophosphatidic acid. Proc. Natl. Acad. Sci. USA 96:5233-5238
26. Fukushima N, Kimura Y, Chun J. 1998. A single receptor encoded by vzg-1/lpA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid. Proc. Natl. Acad. Sci. USA 95:6151-6156
27. Ishii I, Contos JJ, Fukushima N, Chun J. 2000. Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol. Pharmacol. 58:895-902
28. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J. 2000. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl. Acad. Sci. USA 97:13384-13389
29. Weiner JA, Fukushima N, Contos JJ, Scherer SS, Chun J. 2001. Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J. Neurosci. 21:7069-7078
30. Contos JJ, Ishii I, Fukushima N, Kingsbury MA, Ye X, et al. 2002. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol. Cell. Biol. 22:6921-6929
31. Estivill-Torrus G, Llebrez-Zayas P, Matas-Rico E, Santin L, Pedraza C, et al. 2008. Absence of LPA1 signaling results in defective cortical development. Cereb. Cortex 18:938-950
32. Contos JJ, Chun J. 2000. Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA. Genomics 64:155-169
33. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, et al. 2000. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 478:159-165
34. Goetzl EJ, Kong Y, Mei B. 1999. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J. Immunol. 162:2049-2056
35. Deng W, Balazs L, Wang DA, Van Middlesworth L, Tigyi G, et al. 2002. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation-and chemotherapy-induced apoptosis. Gastroenterology 123:206-216
36. Zheng Y, Kong Y, Goetzl EJ. 2001. Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J. Immunol. 166:2317-2322
37. Zheng Y, Voice JK, Kong Y, Goetzl EJ. 2000. Altered expression and functional profile of lysophos-phatidic acid receptors in mitogen-activated human blood T lymphocytes. FASEB J. 14:2387-2389
38. Panchatcharam M, Miriyala S, Yang F, Rojas M, End C, et al. 2008. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ. Res. 103:662-670
39. Yun CC, Sun H, Wang D, Rusovici R, Castleberry A, et al. 2005. LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am. J. Physiol. Cell. Physiol. 289:C2-11
40. Yu S, Murph MM, Lu Y, Liu S, Hall HS, et al. 2008. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl. Cancer Inst. 100:1630-1642
41. Chen M, Towers LN, O'Connor KL. 2007. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am. J. Physiol. Cell. Physiol. 292:C1927-33
42. Lai YJ, Chen CS, Lin WC, Lin FT. 2005. c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol. Cell. Biol. 25:5859-5868
43. Lai YJ, Lin WC, Lin FT. 2007. PTPL1/FAP-1 negatively regulates TRIP6 functionin lysophosphatidic acid-induced cell migration. J. Biol. Chem. 282:24381-24387
44. Lin FT, Lai YJ. 2008. Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated protein-protein interactions. Biochim. Biophys. Acta 1781:558-562
45. Komachi M, Tomura H, Malchinkhuu E, Tobo M, Mogi C, et al. 2009. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis 30:457-465
46. Kingsbury MA, Rehen SK, Contos JJ, Higgins CM, Chun J. 2003. Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat. Neurosci. 6:1292-1299
47. Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, et al. 1999. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 274:27776-27785
48. Im DS, Heise CE, Harding MA, George SR, O'Dowd BF, et al. 2000. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol. Pharmacol. 57:753-759
49. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, et al. 2005. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435:104-108
50. Hama K, Aoki J, Bandoh K, Inoue A, Endo T, et al. 2006. Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus. Life Sci. 79:1736-1740
51. Sonoda H, Aoki J, Hiramatsu T, Ishida M, Bandoh K, et al. 2002. A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid. J. Biol. Chem. 277:34254-34263
52. Janssens R, Boeynaems JM, Godart M, Communi D. 1997. Cloning of a human heptahelical receptor closely related to the P2Y5 receptor. Biochem. Biophys. Res. Commun. 236:106-112
53. O'Dowd BF, Nguyen T, Jung BP, Marchese A, Cheng R, et al. 1997. Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes. Gene 187:75-81
54. Noguchi K, Ishii S, Shimizu T. 2003. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 278:25600-25606
55. Lee CW, Rivera R, Dubin AE, Chun J. 2007. LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J. Biol. Chem. 282:4310-4317
56. Yanagida K, Ishii S, Hamano F, Noguchi K, Shimizu T. 2007. LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line. J. Biol. Chem. 282:5814-5824
57. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, et al. 2006. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther. 318:619-628
58. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. 2006. GPR92 as a new G12/13-and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 281:23589-23597
59. Oh DY, Yoon JM, Moon MJ, Hwang JI, Choe H, et al. 2008. Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J. Biol. Chem. 283:21054-21064
60. Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, et al. 2009. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J. Biol. Chem. 284:17304-17319
61. Yin H, Chu A, Li W, Wang B, Shelton F, et al. 2009. Lipid G protein-coupled receptor ligand identification using {beta}-arrestin PathHunterTM assay. J. Biol. Chem. 284:12328-12338
62. Murakami M, Shiraishi A, Tabata K, Fujita N. 2008. Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 371:707-712
63. Pasternack SM, von Kugelgen I, Aboud KA, Lee YA, Ruschendorf F, et al. 2008. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat. Genet. 40:329-334
64. Shimomura Y, Wajid M, Ishii Y, Shapiro L, Petukhova L, et al. 2008. Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair. Nat. Genet. 40:335-339
65. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N. 2007. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 363:861-866
66. 6. J. Biol. Chem. 284:17731-17741
67. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, et al. 2003. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. USA 100:131-136
68. Sen S, Smeby RR, Bumpus FM. 1968. Antihypertensive effect of an isolated phospholipid. Am. J. Physiol. 214:337-341
69. Tokumura A, Fukuzawa K, Tsukatani H. 1978. Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species. Lipids 13:572-574
70. Anliker B, Chun J. 2004. Cell surface receptors in lysophospholipid signaling. Semin. Cell. Dev. Biol. 15:457-465
71. Noguchi K, Herr D, Mutoh T, Chun J. 2009. Lysophosphatidic acid (LPA) and its receptors. Curr. Opin. Pharmacol. 9:15-23
72. Harrison SM, Reavill C, Brown G, Brown JT, Cluderay JE, et al. 2003. LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease. Mol. Cell. Neurosci. 24:1170-1179
73. Campbell DS, Holt CE. 2001. Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation. Neuron 32:1013-1026
74. Fukushima N, Weiner JA, Chun J. 2000. Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. Dev. Biol. 228:6-18
75. Yuan XB, Jin M, Xu X, Song YQ, Wu CP, et al. 2003. Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nat. Cell Biol. 5:38-45
76. Fukushima N,Weiner JA, Kaushal D, Contos JJ, Rehen SK, et al. 2002. Lysophosphatidic acid influences the morphology and motility of young, postmitotic cortical neurons. Mol. Cell. Neurosci. 20:271-282
77. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, et al. 2004. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat. Med. 10:712-718
78. InoueM,Xie W, MatsushitaY,ChunJ,AokiJ,et al. 2008. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience 152:296-298
79. Inoue M, Yamaguchi A, Kawakami M, Chun J, Ueda H. 2006. Loss of spinal substance P pain transmission under the condition of LPA1 receptor-mediated neuropathic pain. Mol. Pain. 2:25
80. Svetlov SI, Ignatova TN, Wang KK, Hayes RL, English D, et al. 2004. Lysophosphatidic acid induces clonal generation of mouse neurospheres via proliferation of Sca-1-and AC133-positive neural progenitors. Stem Cells Dev. 13:685-693
81. Rhee HJ, Nam JS, Sun Y, Kim MJ, Choi HK, et al. 2006. Lysophosphatidic acid stimulates cAMP accumulation and cAMP response element-binding protein phosphorylation in immortalized hippocampal progenitor cells. Neuroreport 17:523-526
82. Dubin AE, Bahnson T, Weiner JA, Fukushima N, Chun J. 1999. Lysophosphatidic acid stimulates neurotransmitter-like conductance changes that precede GABA and L-glutamate in early, presumptive cortical neuroblasts. J. Neurosci. 19:1371-1381
83. Matas-Rico E, Garcia-Diaz B, Llebrez-Zayas P, Lopez-Barroso D, Santin L, et al. 2008. Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus. Mol. Cell. Neurosci. 39:342-355
84. LloydB,Tao Q, Lang S,WylieC. 2005. Lysophosphatidic acid signaling controls cortical actin assembly and cytoarchitecture in Xenopus embryos. Development 132:805-816
85. Jalink K, Eichholtz T, Postma FR, van Corven EJ, Moolenaar WH. 1993. Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Differ. 4:247-255
86. 2+ signaling and Rho. J. Neurochem. 66:537-548
87. Holtsberg FW, Steiner MR, Bruce-Keller AJ, Keller JN, Mattson MP, et al. 1998. Lysophosphatidic acid and apoptosis of nerve growth factor-differentiated PC12 cells. J. Neurosci. Res. 53:685-696
88. Zheng ZQ, Fang XJ, Qiao JT. 2004. Dual action of lysophosphatidic acid in cultured cortical neurons: survival and apoptogenic. Sheng Li Xue Bao. 56:163-171
89. Pilpel Y, Segal M. 2006. The role of LPA1 in formation of synapses among cultured hippocampal neurons. J. Neurochem. 97:1379-1392
90. Trimbuch T, BeedP,Vogt J,Schuchmann S,MaierN,et al. 2009. Synaptic PRG-1 modulates excitatory transmission via lipid phosphate-mediated signalling. Cell 138(6):1222-1235
91. Shano S, Moriyama R, Chun J, Fukushima N. 2008. Lysophosphatidic acid stimulates astrocyte proliferation through LPA(1). Neurochem. Int. 52:216-220
92. Keller JN, Steiner MR, Holtsberg FW, Mattson MP, Steiner SM. 1997. Lysophosphatidic acid-induced proliferation-related signals in astrocytes. J. Neurochem. 69:1073-1084
93. Rao TS, Lariosa-Willingham KD, Lin FF, Palfreyman EL, Yu N, et al. 2003. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res. 990:182-194
94. Sorensen SD, Nicole O, Peavy RD, Montoya LM, Lee CJ, et al. 2003. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol. Pharmacol. 64:1199-1209
95. Manning TJ Jr, Sontheimer H. 1997. Bovine serum albumin and lysophosphatidic acid stimulate calcium mobilization and reversal of cAMP-induced stellation in rat spinal cord astrocytes. Glia 20:163-172
96. Suidan HS, Nobes CD, Hall A, Monard D. 1997. Astrocyte spreading in response to thrombin and lysophosphatidic acid is dependent on the Rho GTPase. Glia 21:244-252
97. de Sampaio ESTC, Choi JW, Gardell SE, Herr DR, Rehen SK, et al. 2008. Lysophosphatidic acid receptor-dependent secondary effects via astrocytes promote neuronal differentiation. J. Biol. Chem. 283:7470-7479
98. Moller T, Contos JJ, Musante DB, Chun J, Ransom BR. 2001. Expression and function of lysophos-phatidic acid receptors in cultured rodent microglial cells. J. Biol. Chem. 276:25946-25952
99. Tham CS, Lin FF, Rao TS, Yu N, Webb M. 2003. Microglial activation state and lysophospholipid acid receptor expression. Int. J. Dev. Neurosci. 21:431-443
100. Fujita R, Ma Y, Ueda H. 2008. Lysophosphatidic acid-induced membrane ruffling and brain-derived neurotrophic factor gene expression are mediated by ATP release in primary microglia. J. Neurochem. 107:152-160
101. (+) channels. Neuroscience 109:827-835
102. + channels for lysophosphatidic acid-induced microglial migration. Eur. J. Neurosci. 19:1469-1474
103. Allard J, Barron S, Diaz J, Lubetzki C, Zalc B, et al. 1998. A rat G protein-coupled receptor selectively expressed in myelin-forming cells. Eur. J. Neurosci. 10:1045-1053
104. Yu N, Lariosa-Willingham KD, Lin FF, Webb M, Rao TS. 2004. Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia 45:17-27
105. Cervera P, Tirard M, Barron S, Allard J, Trottier S, et al. 2002. Immunohistological localization of the myelinating cell-specific receptor LP(A1). Glia 38:126-136
106. Stankoff B, Barron S, Allard J, Barbin G, Noel F, et al. 2002. Oligodendroglial expression of Edg-2 receptor: developmental analysis and pharmacological responses to lysophosphatidic acid. Mol. Cell. Neurosci. 20:415-428
107. Nogaroli L, Yuelling LM, Dennis J, Gorse K, Payne SG, et al. 2009. Lysophosphatidic acid can support the formation of membranous structures and an increase in MBP mRNA levels in differentiating oligodendrocytes. Neurochem. Res. 34:182-193
108. Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, et al. 2005. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 25:1459-1469
109. Li Y, Gonzalez MI, Meinkoth JL, Field J, Kazanietz MG, et al. 2003. Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells. J. Biol. Chem. 278:9585-9591
110. Frohnert PW, Stonecypher MS, Carroll SL. 2003. Lysophosphatidic acid promotes the proliferation of adult Schwann cells isolated from axotomized sciatic nerve. J. Neuropathol. Exp. Neurol. 62:520-529
111. Hennessy RJ, Baldwin PA, Browne DJ, Kinsella A, Waddington JL. 2007. Three-dimensional laser surface imaging and geometric morphometrics resolve frontonasal dysmorphology in schizophrenia. Biol. Psychiatry 61:1187-1194
112. Moriwaki M, Kishi T, Takahashi H, Hashimoto R, Kawashima K, et al. 2009. Prepulse inhibition of the startle response with chronic schizophrenia: A replication study. Neurosci. Res. 65(3):259-262
113. González-Maeso J, Sealfon SC. 2009. Psychedelics and schizophrenia. Trends Neurosci. 32:225-232
114. Quincozes-Santos A, Abib RT, Leite MC, Bobermin D, Bambini-Junior V, et al. 2008. Effect of the atypical neuroleptic risperidone on morphology and S100B secretion in C6 astroglial lineage cells. Mol. Cell. Biochem. 314:59-63
115. Brimacombe M, Ming X, Lamendola M. 2007. Prenatal and birth complications in autism. Matern. Child Health J. 11:73-79
116. Byrne M, Agerbo E, Bennedsen B, Eaton WW, Mortensen PB. 2007. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr. Res. 97:51-59
117. Tokumura A, Iimori M, Nishioka Y, Kitahara M, Sakashita M et al. 1994. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am. J. Physiol. Cell Physiol. 267:C204-10
118. Baker DL, Desiderio DM, Miller DD, TolleyB, Tigyi GJ. 2001. Direct quantitative analysisoflysophos-phatidic acid molecular speciesbystable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal. Biochem. 292:287-295
119. Hardan AY, Jou RJ, Keshavan MS, Varma R, Minshew NJ. 2004. Increased frontal cortical folding in autism: a preliminary MRI study. Psychiatry Res. 131:263-268
120. Nakamura M, Nestor PG, McCarley RW, Levitt JJ, Hsu L, et al. 2007. Altered orbitofrontal sulcogyral pattern in schizophrenia. Brain 130:693-707
121. DottoriM,LeungJ,TurnleyAM, PebayA.2008. Lysophosphatidic acid inhibits neuronal differentiation of neural stem/progenitor cells derived from human embryonic stem cells. Stem Cells 26:1146-1154
122. Renback K, Inoue M, Ueda H. 1999. Lysophosphatidic acid-induced, pertussis toxin-sensitive nocicep-tion through a substance P release from peripheral nerve endings in mice. Neurosci. Lett. 270:59-61
123. Renback K, Inoue M, Yoshida A, Nyberg F, Ueda H. 2000. Vzg-1/lysophosphatidic acid-receptor involved in peripheral pain transmission. Brain Res. Mol. Brain Res. 75:350-354
124. Inoue M, Ma L, Aoki J, Chun J, Ueda H. 2008. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol. Pain. 4:6
125. Brault S, Gobeil F Jr, Fortier A, Honore JC, Joyal JS, et al. 2007. Lysophosphatidic acid induces endothelial cell death by modulating the redox environment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292:R1174-83
126. Neidlinger NA, Larkin SK, Bhagat A, Victorino GP, Kuypers FA. 2006. Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J. Biol. Chem. 281:775-781
127. Panetti TS, Chen H, Misenheimer TM, Getzler SB, Mosher DF. 1997. Endothelial cell mitogenesis induced byLPA: inhibition by thrombospondin-1 and thrombospondin-2. J. Lab. Clin. Med. 129:208-216
128. LeeH,Goetzl EJ, An S.2000. Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am. J. Physiol. Cell. Physiol. 278:C612-18
129. Wu WT, Chen CN, Lin CI, Chen JH, Lee H. 2005. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology 146:3387-3400
130. Tigyi G, Hong L, Yakubu M, Parfenova H, Shibata M, et al. 1995. Lysophosphatidic acid alters cere-brovascular reactivity in piglets. Am. J. Physiol. Heart Circ. Physiol. 268:H2048-55
131. Siess W. 2002. Athero-and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim. Biophys. Acta 1582:204-215
132. Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, et al. 1999. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 96:6931-6936
133. Rother E, Brandl R, Baker DL, Goyal P, Gebhard H, et al. 2003. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 108:741-747
134. Pamuklar Z, Federico L, Liu S, Umezu-Goto M, Dong A, et al. 2009. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J. Biol. Chem. 284:7835-7894
135. Hayashi K, Takahashi M, Nishida W, Yoshida K, Ohkawa Y, et al. 2001. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ. Res. 89:251-258
136. Kim J, Keys JR, Eckhart AD. 2006. Vascular smooth muscle migration and proliferation in response to lysophosphatidic acid (LPA) is mediated by LPA receptors coupling to Gq. Cell. Signal. 18:1695-1701
137. Pilquil C, Dewald J, Cherney A, Gorshkova I, Tigyi G, et al. 2006. Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation. J. Biol. Chem. 281:38418-38429
138. Balazs L, Okolicany J, Ferrebee M, Tolley B, Tigyi G. 2001. Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280:R466-72
139. Demoyer JS, Skalak TC, Durieux ME. 2000. Lysophosphatidic acid enhances healing ofacute cutaneous wounds in the mouse. Wound Repair Regen. 8:530-537
140. Sturm A, Dignass AU. 2002. Modulation of gastrointestinal wound repair and inflammation by phos-pholipids. Biochim. Biophys. Acta 1582:282-288
141. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, et al. 2004. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J. Biol. Chem. 279:17634-17639
142. Tager AM, Lacamera P, Shea BS, Campanella GS, Selman M, et al. 2008. The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis tolung injuryby mediatingfibroblast recruitment and vascular leak. Nat. Med. 14:45-54
143. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, et al. 2006. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355:1124-1140
144. Georas SN, Berdyshev E, Hubbard W, Gorshkova IA, Usatyuk PV, et al. 2007. Lysophosphatidic acid is detectable in human bronchoalveolar lavage fluids at baseline and increased after segmental allergen challenge. Clin. Exp. Allergy 37:311-322
145. Zhao Y, Natarajan V. 2009. Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling. Cell. Signal 21:367-377
146. Goetzl EJ, Kong Y, Voice JK. 2000. Cutting edge: differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes. J. Immunol. 164:4996-4999
147. Rubenfeld J, Guo J, Sookrung N, Chen R, Chaicumpa W, et al. 2006. Lysophosphatidic acid enhances interleukin-13 gene expression and promoter activity in T cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 290:L66-74
148. Panther E, Idzko M, Corinti S, Ferrari D, Herouy Y, et al. 2002. The influence of lysophosphatidic acid on the functions of human dendritic cells. J. Immunol. 169:4129-4135
149. Chen R, Roman J, Guo J, West E, McDyer J, et al. 2006. Lysophosphatidic acid modulates the activation of human monocyte-derived dendritic cells. Stem Cells Dev. 15:797-804
150. Chan LC, Peters W, Xu Y, Chun J, Farese RV Jr, et al. 2007. LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). J. Leukoc. Biol. 82:1193-1200
151. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, et al. 2008. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat. Immunol. 9:415-423
152. Budnik LT, Mukhopadhyay AK. 2002. Lysophosphatidic acid and its role in reproduction. Biol. Reprod. 66:859-865
153. Tokumura A, Kanaya Y, Miyake M, Yamano S, Irahara M, et al. 2002. Increased production of bioactive lysophosphatidic acid by serum lysophospholipase D in human pregnancy. Biol. Reprod. 67:1386-1392
154. Yue J, Yokoyama K, Balazs L, Baker DL, Smalley D, et al. 2004. Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level. Cell. Signal. 16:385-399
155. Ye X, Skinner MK, Kennedy G, Chun J. 2008. Age-dependent loss of sperm production in mice via impaired lysophosphatidic acid signaling. Biol. Reprod. 79:328-336
156. Garbi M, Rubinstein S, Lax Y, Breitbart H. 2000. Activation of protein kinase calpha in the lysophos-phatidic acid-induced bovine sperm acrosome reaction and phospholipase D1 regulation. Biol. Reprod. 63:1271-1277
157. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R,et al. 1997. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91:197-208
158. Hama K, Aoki J, Inoue A, Endo T, Amano T, et al. 2007. Embryo spacing and implantation timing are differentially regulated by LPA3-mediated lysophosphatidic acid signaling in mice. Biol. Reprod. 77:954-959
159. Song H, Lim H, Paria BC, Matsumoto H, Swift LL, et al. 2002. Cytosolic phospholipase A2alpha is crucial for 'on-time' embryo implantation that directs subsequent development. Development 129:2879-2889
160. Mohamed OA, Jonnaert M, Labelle-Dumais C, Kuroda K, Clarke HJ, et al. 2005. Uterine Wnt/beta-catenin signaling is required for implantation. Proc. Natl. Acad. Sci. USA 102:8579-8584
161. De Alvarez RR, Goodell BW. 1964. Serum lipid partitions and fatty acid composition (using gas chro-matography) in gynecological cancer. Am. J. Obstet. Gynecol. 88:1039-1062
162. Imamura F, Horai T, Mukai M, Shinkai K, Sawada M, et al. 1993. Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D. Biochem. Biophys. Res. Commun. 193:497-503
163. Xu Y, Fang XJ, Casey G, Mills GB. 1995. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 309:933-940
164. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, et al. 1995. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. 1:1223-1232
165. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, et al. 1998. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. [see comments]. JAMA 280:719-723
166. Baker DL, Morrison P, Miller B, Riely CA, Tolley B, et al. 2002. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 287:3081-3082
167. Frankel A, Mills GB. 1996. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin. Cancer Res. 2:1307-1313
168. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, et al. 1999. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin. Cancer Res. 5:3704-3710
169. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. 2001. Lysophosphatidic acid promotes matrix met-alloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 61:3194-3199
170. Baudhuin LM, Cristina KL, Lu J, Xu Y. 2002. Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific. Mol. Pharmacol. 62:660-671
171. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, et al. 2001. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst. 93:762-768
172. Bian D, Su S, Mahanivong C, Cheng RK, Han Q, et al. 2004. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res. 64:4209-4217
173. Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, et al. 2009. LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol. Oncol. 112:215-223
174. Goetzl EJ, Dolezalova H, Kong Y, Hu YL, Jaffe RB, et al. 1999. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. 59:5370-5375
175. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, et al. 2006. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. USA 103:9643-9648
176. Symowicz J, Adley BP, Woo MM, Auersperg N, Hudson LG, et al. 2005. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res. 65:2234-2242
177. Huang RY, Wang SM, Hsieh CY, Wu JC. 2008. Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120-catenin. Int. J. Cancer 123:801-809
178. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, et al. 2006. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res. 66:7983-7990
179. Shida D, Kitayama J, Yamaguchi H, Okaji Y, Tsuno NH, et al. 2003. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 63:1706-1711
180. Rusovici R, Ghaleb A, Shim H, Yang VW, Yun CC. 2007. Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. Biochim. Biophys. Acta 1770:1194-1203
181. Lin S, Wang D, Iyer S, Ghaleb AM, Shim H, et al. 2009. The absence of LPA(2) attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology 136:1711-1720
182. Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, et al. 2005. Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells. Biochem. Biophys. Res. Commun. 327:907-914
183. Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, et al. 2005. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc. Natl. Acad. Sci. USA 102:6027-6032
184. Shida D, Fang X, Kordula T, Takabe K, Lepine S, et al. 2008. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 68:6569-6577
185. Yamada T, Yano S, Ogino H, Ikuta K, Kakiuchi S, et al. 2008. Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2. Cancer Sci. 99:1603-1610
186. Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, et al. 2004. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 6:R640-46
187. Murph MM, Hurst-Kennedy J, Newton V, Brindley DN, Radhakrishna H. 2007. Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells. Mol. Cancer Res. 5:1201-1211
188. Hao F, Tan M, Xu X, Han J, Miller DD, et al. 2007. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim. Biophys. Acta 1771:883-892
189. KishiY,OkudairaS, Tanaka M, HamaK,ShidaD,et al. 2006. Autotaxinisoverexpressedinglioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J. Biol. Chem. 281:17492-17500
190. Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, et al. 2006. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res. 66:3006-3014
191. Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, et al. 2007. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett. 258:63-69
192. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, et al. 2009. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin. Cancer Res. 15:492-501
193. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, et al. 2006. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 66:221-231
194. van Meeteren LA, Brinkmann V, Saulnier-Blache JS, Lynch KR, Moolenaar WH. 2008. Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Lett. 266:203-208
195. Pradere JP, Klein J, Gres S, Guigne C, Neau E, et al. 2007. LPA1 receptor activation promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 18:3110-3118
196. Heusinger-Ribeiro J, Eberlein M, Wahab NA, Goppelt-Struebe M. 2001. Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP. J. Am. Soc. Nephrol. 12:1853-1861
197. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, et al. 2007. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci. 81:1009-1015
198. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, et al. 2007. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J. Clin. Gastroenterol. 41:616-623
199. Ikeda H, Yatomi Y, Yanase M, Satoh H, Nishihara A, et al. 1998. Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem. Biophys. Res. Commun. 248:436-440
200. Valet P, Pages C, Jeanneton O, Daviaud D, Barbe P, et al. 1998. Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth. J. Clin. Investig. 101:1431-1438
201. Pages C, Daviaud D, An S, Krief S, Lafontan M, et al. 2001. Endothelial differentiation gene-2 receptor is involved in lysophosphatidic acid-dependent control of 3T3F442A preadipocyte proliferation and spreading. J. Biol. Chem. 276:11599-11605
202. Ferry G, Tellier E, Try A, Gres S, Naime I, et al. 2003. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J. Biol. Chem. 278:18162-18169
203. Boucher J, Quilliot D, Praderes JP, Simon MF, Gres S, et al. 2005. Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 48:569-577
204. Simon MF, Daviaud D, Pradere JP, Gres S, Guigne C, et al. 2005. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxi-some proliferator-activated receptor gamma2. J. Biol. Chem. 280:14656-14662
205. Yea K, Kim J, Lim S, Park HS, Park KS, et al. 2008. Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake. J. Mol. Med. 86:211-220
206. Gajewiak J, Tsukahara R, Fujiwara Y, Tigyi G, Prestwich GD. 2008. Synthesis, pharmacology, and cell biology of sn-2-aminooxy analogues of lysophosphatidic acid. Org. Lett. 10:1111-1114
207. Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, et al. 2007. Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. Chem. Med. Chem. 2:679-690
208. Okusa MD, Ye H, Huang L, Sigismund L, Macdonald T, et al. 2003. Selective blockade of lysophos-phatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 285:F565-74
209. Pebay A, Bonder CS, Pitson SM. 2007. Stem cell regulation by lysophospholipids. Prostaglandins Other Lipid Mediat. 84:83-97